Another billion dollar deal in the PD-(L)1xVEGF BsAb space

⭐ BioNTech SE and Bristol Myers Squibb entered into a global strategic partnership with a 50/50 profit/loss split to co-develop and co-commercialize BNT327 (PD-L1xVEGF-A BsAb) across numerous solid tumor types (Ref 1).

⭐ BMS will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028.

⭐ In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.

⭐ BioNTech obtained BNT327 through the acquisition of Biotheus in a ~$950 million deal (Ref 2).

📝 To know further details about current development status of BNT327, and competitive landscape of BsAbs, please write to us at support@oncofocus.com.

🌐 References:

1) https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx

2) https://investors.biontech.de/news-releases/news-release-details/biontech-completes-acquisition-biotheus